Ocuphire Pharma Return on Equity

Ocuphire Pharma (OCUP) currently reports a ROE of 828.66%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Ocuphire Pharma's ROE history and peer comparisons.

Ocuphire Pharma's ROE of 828.66% is higher than the Healthcare sector average of -75.59%. That is roughly 1196.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Ocuphire Pharma's current 828.66% should be judged against Healthcare norms (sector average: -75.59%) and against OCUP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 828.66%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Ocuphire Pharma, and consider following OCUP for alerts when major investors trade the stock.

Ocuphire Pharma is classified in the Healthcare sector. On ROE, it currently shows 828.66% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OCUP with unrelated industries.